Immunotherapy Research Continues to Offer Hope

Cancer genetics and the growing knowledge of biology continue to change cancer treatment practices. Now chemotherapy and radiotherapy are beginning to be replaced by treatments that activate a person's immune system and aim to destroy tumors: immunotherapies. A potential new target molecule for cancer immunotherapy was revealed by research from a team at Heidelberg University in Germany, including 2 Turkish scientists, published on 19 August in Cell journal.
The research team studied the dioxin receptor, which is activated by a metabolic enzyme produced in large amounts by tumor cells, IL4I1. They found that it promotes the spread of tumor cells and suppresses the immune system. New findings presented in the published paper suggest that substances inhibiting IL4I1 could offer new opportunities for cancer treatment.
Although many important successes have been achieved with immunotherapies that activate the body's own defenses against tumors, the number of patients benefiting from treatment remains limited. To overcome this problem and enable more patients to benefit, scientists continue investigating the mechanisms tumors use to evade the immune system. This research is extremely important for developing more effective treatment protocols.
The aryl hydrocarbon receptor (AhR), also called the dioxin receptor, mediates the toxic effects of dioxins. In addition, the body's metabolic products of tryptophan, an amino acid needed for protein production and obtained from food, can also activate AhR receptors. Tumor cells use these metabolic products to their advantage to increase their mobility and weaken the immune response.
In light of this knowledge, one molecule in particular attracted scientists' attention: the IL4I1 enzyme. They found that tryptophan is metabolized by the IL4I1 enzyme and binds to the dioxin receptor, activating it and thereby suppressing immune system cells. The researchers also emphasize that no other enzyme is as powerful at activating the dioxin receptor.
What do the study results show us?
Having discovered that the IL4I1 enzyme suppresses antitumor properties, the researchers continued studies in different tumor models to verify the findings. Glioma (brain tumor) patients who produce high amounts of the IL4I1 enzyme had a lower probability of survival; in skin cancer patients, they observed that this enzyme was responsible for resistance to treatment. In mouse models, they also showed that the IL4I1 enzyme affects the immune system in chronic lymphatic leukemia, a type of blood cancer, causing cancer progression. Conversely, when environmental or genetic changes mean that the IL4I1 enzyme cannot be produced in animal models, they demonstrated that the immune system successfully prevents cancer progression.
The study's GRAPHICAL ABSTRACT can be seen below:

All these new data show that IL4I1 has great potential as a drug target. The failure of clinical trials targeting enzymes involved in tryptophan metabolism other than the IL4I1 enzyme indicates that the IL4I1 enzyme should be tested as a target molecule. Finding a new immunotherapy target through further research offers hope for the treatment of many cancers.
Sources
IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression.
Cell 2020
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.